title: [Vitamin K epoxide reductase: Fresh blood for oral anticoagulant therapies].
abstract: BACKGROUND
  Vitamin K epoxide reductase complex subunit I (VKORC1) is a key enzyme in the vitamin K cycle, cofactor required for the activation of vitamin K-dependent clotting factors.
  
  
  METHODS
  VKORC1 recycles vitamin K 2,3 epoxide back to active vitamin K hydroquinone, an important factor for the carboxylation step of clotting factors. VKORC1 is the target enzyme of inhibition by oral anticoagulants or anti-vitamin K (warfarin, acenocoumarol).
  
  
  CONCLUSIONS
  We show here the clinical consequences of genetic variations of VKORC1 during VKA therapy.
authors.affiliation: Inserm UMR-S775, service de toxicologie moléculaire, université René-Descartes, centre universitaire des Saints-Pères, 45, rue des Saints-Pères, 75006 Paris, France. marie-anne.loriot@univ-paris5.fr
authors.forename: M-A
authors.initials: MA
authors.lastname: Loriot
authors.forename: P
authors.initials: P
authors.lastname: Beaune
mesh_terms: D000284:Administration, Oral; D000465:Algorithms; D000925:Anticoagulants / Q000494:pharmacology*; D004351:Drug Resistance / Q000235:genetics; D006801:Humans; D006899:Mixed Function Oxygenases / Q000235:genetics* / Q000378:metabolism; D009154:Mutation; D011110:Polymorphism, Genetic; D014812:Vitamin K / Q000235:genetics / Q000378:metabolism*; D064417:Vitamin K Epoxide Reductases
chemical_list: D000925:Anticoagulants; D014812:Vitamin K; D006899:Mixed Function Oxygenases; C578523:VKORC1 protein, human; D064417:Vitamin K Epoxide Reductases